Ian M Kronish1, Ying Kuen Cheung2, Daichi Shimbo3, Jacob Julian3, Benjamin Gallagher4, Faith Parsons3, Karina W Davidson3. 1. Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, 622 West 168th Street, PH9-311, New York, NY, 10032, USA. ik2293@columbia.edu. 2. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA. 3. Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, 622 West 168th Street, PH9-311, New York, NY, 10032, USA. 4. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA.
Abstract
BACKGROUND: There are substantial differences in the effects of blood pressure (BP) medications in individual patients. Yet, the current standard approach to prescribing BP medications is not personalized. OBJECTIVE: To determine the feasibility of individualizing the selection of BP medications through pragmatic personalized (i.e., N-of-1) trials. DESIGN: Series of N-of-1 trials. SETTING: Outpatient. PATIENTS: Hypertensive adults prescribed none or one BP medication. INTERVENTION: Participation in a flexible, open-label personalized trial of two to three BP medications (NCT02744456). MEASUREMENTS: BP was measured twice per day with a validated home BP device. Frequency and severity of side effects were assessed at the end of the day via an electronic questionnaire. Patients' BP medication preference was assessed after reviewing BP lowering and side effect results with a study clinician. Feasibility was assessed by determining the proportion of patients who adhered to self-assessments. Benefit was assessed by asking patients to rate the helpfulness of participation and whether they would recommend personalized trials to other hypertensive patients. KEY RESULTS: Of ten patients enrolled, two dropped out prior to initiation, one discovered white coat hypertension through ambulatory BP monitoring, and seven (mean age 58 years, 71% of women) completed personalized trials. All seven were compliant with home BP monitoring and side effect tracking. All seven recommended personalized trials of BP medications to others. Thiazides were preferred by three patients, renin-angiotensin system-blocking agents by two patients, a combination of thiazide and beta-blocker by one patient, and any of three classes by one patient. CONCLUSIONS: Personalized trials of BP medications were feasible and led to improved treatment precision. Heterogeneity of patient preferences and of therapeutic BP response for first-line BP medications can be determined through a personalized trial approach.
BACKGROUND: There are substantial differences in the effects of blood pressure (BP) medications in individual patients. Yet, the current standard approach to prescribing BP medications is not personalized. OBJECTIVE: To determine the feasibility of individualizing the selection of BP medications through pragmatic personalized (i.e., N-of-1) trials. DESIGN: Series of N-of-1 trials. SETTING:Outpatient. PATIENTS: Hypertensive adults prescribed none or one BP medication. INTERVENTION: Participation in a flexible, open-label personalized trial of two to three BP medications (NCT02744456). MEASUREMENTS: BP was measured twice per day with a validated home BP device. Frequency and severity of side effects were assessed at the end of the day via an electronic questionnaire. Patients' BP medication preference was assessed after reviewing BP lowering and side effect results with a study clinician. Feasibility was assessed by determining the proportion of patients who adhered to self-assessments. Benefit was assessed by asking patients to rate the helpfulness of participation and whether they would recommend personalized trials to other hypertensivepatients. KEY RESULTS: Of ten patients enrolled, two dropped out prior to initiation, one discovered white coat hypertension through ambulatory BP monitoring, and seven (mean age 58 years, 71% of women) completed personalized trials. All seven were compliant with home BP monitoring and side effect tracking. All seven recommended personalized trials of BP medications to others. Thiazides were preferred by three patients, renin-angiotensin system-blocking agents by two patients, a combination of thiazide and beta-blocker by one patient, and any of three classes by one patient. CONCLUSIONS: Personalized trials of BP medications were feasible and led to improved treatment precision. Heterogeneity of patient preferences and of therapeutic BP response for first-line BP medications can be determined through a personalized trial approach.
Entities:
Keywords:
clinical trials; disease management; health care delivery; hypertension; primary care
Authors: Alison J Deary; Anne L Schumann; Helen Murfet; Stephen F Haydock; Roger S-Y Foo; Morris J Brown Journal: J Hypertens Date: 2002-04 Impact factor: 4.844
Authors: G H Guyatt; R B Haynes; R Z Jaeschke; D J Cook; L Green; C D Naylor; M C Wilson; W S Richardson Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork Journal: Per Med Date: 2011-03 Impact factor: 2.512
Authors: Thomas G Pickering; Nancy Houston Miller; Gbenga Ogedegbe; Lawrence R Krakoff; Nancy T Artinian; David Goff Journal: Hypertension Date: 2008-05-22 Impact factor: 10.190
Authors: Richard L Kravitz; Naihua Duan; Edmund J Niedzinski; M Cameron Hay; Saskia K Subramanian; Thomas S Weisner Journal: Milbank Q Date: 2008-12 Impact factor: 4.911
Authors: Parag Goyal; Monika M Safford; Sarah N Hilmer; Michael A Steinman; Daniel D Matlock; Mathew S Maurer; Mark S Lachs; Ian M Kronish Journal: Br J Clin Pharmacol Date: 2022-07-13 Impact factor: 3.716
Authors: Patricia K Riggs; Antoine Chaillon; Guochun Jiang; Scott L Letendre; Yuyang Tang; Jeff Taylor; Andrew Kaytes; Davey M Smith; Karine Dubé; Sara Gianella Journal: Curr HIV/AIDS Rep Date: 2022-10-19 Impact factor: 5.495
Authors: Karina W Davidson; Michael Silverstein; Ken Cheung; Rocco A Paluch; Leonard H Epstein Journal: JAMA Pediatr Date: 2021-04-01 Impact factor: 16.193
Authors: Catherine G Derington; Jordan B King; Thomas Delate; Sheila R Botts; Miranda Kroehl; David P Kao; Katy E Trinkley Journal: PLoS One Date: 2020-12-03 Impact factor: 3.240
Authors: Lyndonna Marrast; Joseph Conigliaro; Camille Chan; Eun Ji Kim; Joan Duer-Hefele; Michael A Diefenbach; Karina W Davidson Journal: Per Med Date: 2021-05-28 Impact factor: 2.119
Authors: Ying Kuen Cheung; Dallas Wood; Kangkang Zhang; Ty A Ridenour; Lilly Derby; Tara St Onge; Naihua Duan; Joan Duer-Hefele; Karina W Davidson; Ian Kronish; Nathalie Moise Journal: BMJ Open Date: 2020-06-07 Impact factor: 2.692